scholarly journals Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases

Cancer ◽  
2010 ◽  
Vol 116 (18) ◽  
pp. 4238-4247 ◽  
Author(s):  
Anna Niwińska ◽  
Magdalena Murawska ◽  
Katarzyna Pogoda
Keyword(s):  
Breast Cancer ◽  
Brain Metastases ◽  
Systemic Treatment ◽  
Whole Brain Radiotherapy ◽  
Breast Cancer Subtypes ◽  
Whole Brain ◽  
Cancer Subtypes ◽  
Brain Radiotherapy

Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients

2009 ◽  
Vol 93 (3) ◽  
pp. 379-384 ◽  
Author(s):  
Cyrus Chargari ◽  
◽  
Youlia M. Kirova ◽  
Véronique Diéras ◽  
Pablo Castro Pena ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Brain Metastases ◽  
Cancer Patients ◽  
Whole Brain Radiotherapy ◽  
Breast Cancer Patients ◽  
Whole Brain ◽  
Brain Radiotherapy

scholarly journals Do patients with very few brain metastases from breast cancer benefit from whole-brain radiotherapy in addition to radiosurgery?

2014 ◽  
Vol 9 (1) ◽  
Author(s):  
Dirk Rades ◽  
Stefan Huttenlocher ◽  
Dagmar Hornung ◽  
Oliver Blanck ◽  
Steven E Schild ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Brain Metastases ◽  
Whole Brain Radiotherapy ◽  
Whole Brain ◽  
Brain Radiotherapy

scholarly journals A Case of Brain Metastases from Breast Cancer Treated with Whole-Brain Radiotherapy and Eribulin Mesylate

2012 ◽  
Vol 2012 ◽  
pp. 1-3 ◽  
Author(s):  
Carsten Nieder ◽  
Gro Aandahl ◽  
Astrid Dalhaug
Keyword(s):  
Breast Cancer ◽  
Brain Metastases ◽  
Metastatic Disease ◽  
Local Treatment ◽  
Whole Brain Radiotherapy ◽  
Maximum Size ◽  
Newly Diagnosed ◽  
Eribulin Mesylate ◽  
Whole Brain ◽  
Brain Radiotherapy

Patients with triple receptor-negative breast cancer often develop aggressive metastatic disease, which also might involve the brain. In many cases, systemic and local treatment is needed. It is important to consider the toxicity of chemo- and radiotherapy, especially when newly approved drugs become available. Randomised studies leading to drug approval often exclude patients with newly diagnosed brain metastases. Here we report our initial experience with eribulin mesylate and whole-brain radiotherapy (WBRT) in a heavily pretreated patient with multiple brain, lung, and bone metastases from triple receptor-negative breast cancer. Eribulin mesylate was given after 4 previous lines for metastatic disease. Two weeks after the initial dose, that is, during the first cycle, the patient was diagnosed with 5 brain metastases with a maximum size of approximately 4.5 cm. She continued chemotherapy and received concomitant WBRT with 10 fractions of 3 Gy. After 3 cycles of eribulin mesylate, treatment was discontinued because of newly diagnosed liver metastases and progression in the lungs. No unexpected acute toxicity was observed. The only relevant adverse reactions were haematological events after the third cycle (haemoglobin 9.5 g/dL, leukocytes3.1×109/L). The patient died from respiratory failure 18.5 months from diagnosis of metastatic disease, and 2.7 months from diagnosis of brain metastases. To the best of our knowledge, this is the first report on combined WBRT and eribulin mesylate.

scholarly journals Clinical outcomes in patients with brain metastases from breast cancer treated with single-session radiosurgery or whole brain radiotherapy

2016 ◽  
Vol 125 (Supplement_1) ◽  
pp. 26-30 ◽  
Author(s):  
Michael Mix ◽  
Rania Elmarzouky ◽  
Tracey O'Connor ◽  
Robert Plunkett ◽  
Dheerendra Prasad
Keyword(s):  
Breast Cancer ◽  
Brain Metastases ◽  
Median Survival ◽  
Tumor Volume ◽  
Whole Brain Radiotherapy ◽  
Metastatic Tumor ◽  
Whole Brain ◽  
Receptor Status ◽  
Brain Radiotherapy ◽  
Her 2

OBJECTIVEGamma Knife radiosurgery (GKRS) is used to treat brain metastases from breast cancer (BMB) as the sole treatment or in conjunction with tumor resection and/or whole brain radiotherapy (WBRT). This study evaluates outcomes in BMB based on treatment techniques and tumor biological features.METHODSThe authors reviewed all patients treated with BMB between 2004 and 2014. Patients were identified from a prospectively collected radiosurgery database and institutional tumor registry; 214 patients were identified. Data were collected from aforementioned sources and supplemented with chart review where needed. Independent radiological review was performed for all available brain imaging in those treated with GKRS. Survival analyses are reported using Kaplan-Meier estimates.RESULTSDuring the 10-year study period, 214 patients with BMB were treated; 23% underwent GKRS alone, 46% underwent a combination of GKRS and WBRT, and 31% underwent WBRT alone. Median survival after diagnosis of BMB in those treated with GKRS alone was 21 months, and in those who received WBRT alone it was 3 months. In those treated with GKRS plus WBRT, no significant difference in median survival was observed between those receiving WBRT upfront or in a salvage setting following GKRS (19 months vs 14 months, p = 0.63). The median survival of patients with total metastatic tumor volume of ≤ 7 cm3 versus > 7 cm3 was 20 months vs 7 months (p < 0.001). Human epidermal growth factor receptor-2 (Her-2) positively impacted survival after diagnosis of BMB (19 months vs 12 months, p = 0.03). Estrogen receptor status did not influence survival after diagnosis of BMB. No difference was observed in survival after diagnosis of BMB based on receptor status in those who received WBRT alone.CONCLUSIONSIn this single-institution series of BMB, the addition of WBRT to GKRS did not significantly influence survival, nor did the number of lesions treated with GKRS. Survival after the diagnosis of BMB was most strongly affected by Her-2 positivity and total metastatic tumor volume.

Sign in / Sign up

Export Citation Format

Share Document